Anthera Pharmaceuticals Completes Interim B-Cell Analysis of PEARL-SC Study

Positive preliminary results for new lupus drug currently enrolling in Phase 3 clinical trial

Anthera Pharmaceuticals, Inc., a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation, today announced positive interim biomarker data from the PEARL-SC phase 2b clinical study in patients with systemic lupus erythematosus.

Full story

Advertisement

Comments are closed.